News

06.02.2023

Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality. $5.5M financing led by Taiho Ventures LLC, with the participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company’s technology platform, strengthening the team, and advancing the mitochondria’s GMP manufacturing

News

03.02.2023

cellvie, the leader in Therapeutic Mitochondria Transplantation moves its headquarters to Zürich. The new location features office space, a kitchen and meeting area and, most importantly, more than 100 sqm. state-of-art laboratory. The new office is found in Technopark Zürich, which offers a vibrant setting with around 260 firms of various sizes and stages of development, which come from many different industries.

News

09.11.2022

Cellvie was privileged to be invited as one of Falling Walls Winners that were selected from more than 1300 submissions. Those fortunate presented astonishing innovations ranging from antibody-drug conjugates as next-generation cancer therapy (Tubulis) to quantum computing. Among this stellar competition, cellvie was selected as the Cluster Winner in Health Solutions 2022.

News

14.10.2022

CELLVIE presents at the Rejuvenation Startup Summit organized by Kizoo in Berlin. Dr. Alex Schueller, cellvie’s CEO and co-founder, was one of the distinguished speakers invited from longevity biotech start-ups. Alex presented on the potential of mitochondria as a new treatment modality, not only for ischemia-reperfusion injury but also for aging related degeneration.

News

27.09.2021

Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when blood supply returns after a period of ischemia.

News

17.06.2021

cellvie AG is proud to announce that CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Entrepreneurship Award among >200 applicants

News

28.01.2021

Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

News

18.11.2020

CELLVIE palces among the final 5 contenders for the grant prize of the MedTech Innovator Award and takes home the prestigious MedTech Innovator Value Award

News

10.07.2020

cellvie has been granted orphan-drug designation for the use of mitochondria in the prevention of ischemia-reperfusion injury during solid organ transplantation.